Summary The effect of 10-6M tamoxifen on MCF-7 cells adapted to growth in 0.5% foetal calf serum has been studied. The growth inhibitory effect of this tamoxifen concentration was abolished by simultaneous addition of 10-8M oestradiol, indicating that tamoxifen may exert its effect via binding to the oestrogen receptor. Flow cytometric cell cycle analysis of tamoxifen-treated cultures showed an increase in the proportion of cells in the GI phase of the cell cycle. By exposing the cells to BUdR before flow cytometry the growth fraction was determined and found to be dramatically decreased in tamoxifen-treated cultures. Cells were not only arrested in the G, phase but also in the G2 phase of the cell cycle. A few colonies of MCF-7 cells were resistant to 10 days treatment with 106 M tamoxifen.
The antioestrogen tamoxifen is widely used for treatment of patients with breast cancer. In general, patients with oestrogen receptor-positive tumours have a response rate of 50%, whereas patients with oestrogen receptor-negative tumours have a response rate of only 10% (Mouridsen et al., 1978; Rose et al., 1980) . The effect of tamoxifen has therefore been attributed to the presence of oestrogen receptors.
It is believed that tamoxifen acts by interfering with oestrogen receptor function at some level, though a specific antioestrogen receptor has been reported to exist in human breast cancer , human endometrium , rat liver Winneker & Clark, 1983) , rat uterus (Winneker & Clark, 1983) and in human breast cancer cell lines (Miller & Katzenellenbogen, 1983) . The antioestrogen receptor content is unrelated to the oestrogen receptor content, and the role of the antioestrogen receptor is still unknown. Miller & Katzenellenbogen (1983) suggest that the interaction with the oestrogen receptor and not with the antioestrogen receptor is most likely to be the mechanism underlying the growth inhibitory effects of antioestrogens. Rochefort et al. (1981) (Briand & Lykkesfeldt, 1984) . Depending on the concentration, tamoxifen inhibition was either oestrogen reversible or oestrogen irreversible. In the present work we have used 10-6M tamoxifen, which is the highest concentration of tamoxifen, the effect of which can be abolished by oestradiol. Sutherland and Taylor (1981) and Greene et al. (1981) have studied the effect of cytotoxic concentrations of tamoxifen on the cell cycle kinetics of MCF-7 and found an accumulation of cells in the G, phase. Two recent reports describe the use of lower concentrations of tamoxifen, where the effect can be reversed by oestradiol (Sutherland et al., 1983; Osborne et al., 1983 MEM + Ham's F12 (1:1) supplemented with glutamine 2mM, insulin 6ngml l and 0.5% heat inactivated foetal bovine serum. The cells had been adapted to growth at this serum concentration since passage 247 (Briand and Lykkesfeldt, 1984) ; cells from passage 336 were used in this study. In the experiments growth medium was replaced by the test medium one day after seeding: this consisted of growth medium supplemented with hydrocortisone (10-8M) and prolactin (1 Mgml -1). The flasks were divided into two groups. A tamoxifen group, which received 10-6M tamoxifen dissolved in ethanol (final conc. 0.1%), and a control group to which ethanol was added at a final concentration of 0.1%. The medium was renewed daily during the experiment.
Growth curves Three cultures were trypsinized and the cells counted in a Burker-Turck chamber one day after seeding. These counts represent the cell number at day 0. Three cultures from each group were counted on designated days of the experiment.
Preparation of nuclei for flow cytometry
The cells were removed from the flasks with 1 mM EDTA in a buffer (137mM NaCl, 2.7mM KCI, 8.1mM Na2HPO4, 1.5mM KH2PO4, pH 7.4) and washed twice with this buffer. They were lysed with 1% Triton X-100 in the buffer supplemented with 2mM EGTA, 1.5mM MgCl2, pH 7.2 and citric acid added to a final concentration of 2% (Miller, 1979) . Nuclei were pelleted by centrifugation at 800g for 10min, resuspended in the buffer with 2mM EGTA, 1.5mM MgCl2 and 0.2% Triton X-100, pH 7.2 and stained with propidium iodide or mithramycin.
Flow cytometry
For conventional flow cytometric cell cycle analysis the samples were stained by addition of propidium iodide (50 pg mlF 1, Sigma) and RNase (0.1 mg ml-1, Sigma type lA) for at least 30min. For determination of the growth fraction after incubation with BUdR the samples were stained by addition of mithramycin (20ligml-1, Mithracin , Pfizer) and MgCl2 (25mM) (Swartzendruber, 1977) .
As internal DNA references stained chicken and trout erythrocyte nuclei were added to each sample. Batches of chicken and trout blood cells were kept frozen in buffer (250mM sucrose, 40mM sodium citrate, 5% dimethylsulfoxide, pH 7.6). Aliquots were thawed and lysis buffer added (IOmM Tris, 1 mM EGTA, 1% Nonidet P 40) prior to staining (Vindel0v et al., 1982c 
Statistics
The phase fractions of the DNA histograms were estimated by fitting the observed distributions of fluorescence (deconvolution) by maximum likelihood using a statistical model described earlier (Christensen et al., 1978; Vindelbv et al., 1982b) . The proportion of non cycling cells (Go) in the flow cytometric histograms of DNA from BUdR treated cultures was estimated in a similar manner using mixtures of Gaussians to fit the additional peaks (Vindeliv et al., 1982a) .
Results
The growth curves of control and tamoxifen treated cultures are shown in Figure 1 At days 3, 4, 5, 6, 7 and 10, cells were harvested from control and tamoxifen treated cultures and nuclei prepared and stained for flow cytometric analysis as described in Materials and methods. Figure 2 shows the DNA distribution in control and tamoxifen treated cultures at day 4. From such histograms the distribution of cells in the different phases of the cell cycle was calculated as described above. The number of cells analyzed in each sample was > 10,000, apart from the tamoxifen culture at day 6, where only 5200 cells were analyzed. Even with the low number of cells, the standard error due to deconvolution of the DNA histograms has been shown to be <2% of the total number of cells (Vindeliv et al., 1982b) . The results of these analyses are shown in Figures 3A, 3B and 3C. The effect of tamoxifen on the proportion of cells with a G1 amount of DNA is shown in Figure 3A and it may be seen that already after 3 days of treatment treated for 3-7 days with tamoxifen. At day 10 no difference was observed. Figure 3C shows the proportion of cells in G2 + M and after 4-7 days treatment fewer cells in the tamoxifen treated cultures were in G2 + M than in the control culture. Go and amounts to 2% of the total cell number.
The next peak represents cells with a G1 amount of DNA containing BUdR in one strand. In the tamoxifen cultures the median cell number during the time of exposure to BUdR increased from 3.6 x 104 to 8.5 x 104. The peak representing cells with a G1 amount of DNA without incorporated BUdR is indicated in the figure as Go and represents 43% of the total cell number. A peak with a G2 amount of DNA without BUdR is present in the histogram of tamoxifen treated cells, but not in the control histogram.
Discussion
We have demonstrated that 10-6M tamoxifen inhibits growth in vitro of the human breast cancer cell line, MCF-7 by reducing the growth fraction. Furthermore, we have shown that cells were arrested not only in the G1 phase of the cell cycle as previously described (Osborne et al., 1983; Sutherland et al., 1983) , but also in the G2 phase. The inhibitory effect of 10-6M tamoxifen can be abolished by simultaneous addition of 10-8M oestradiol and no effects on cell cycle kinetics are observed under these conditions. Lower concentrations of tamoxifen also inhibit growth, though to a smaller extent. In agreement with others (Horwitz & McGuire, 1978) we have also found that tamoxifen binds to the oestrogen receptor and the oestrogen receptor-tamoxifen complex translocates to the nucleus. The oestrogen receptor-negative cell line, HBL-100 originating from cells in normal human milk is completely insensitive to tamoxifen concentrations up to 2 x 10-6M (Briand & Lykkesfeldt, 1984) indicating that the oestrogen reversible effect of tamoxifen in MCF-7 cells is mediated via the oestrogen receptor mechanism. Resistance to tamoxifen treatment has been shown in the cell kinetic work of Osborne et al. (1983) , and two human breast cancer cell sublines resistant to tamoxifen have been isolated and characterized (Nawata et al., 1981 , Horwitz et al., 1982 . Sutherland et al. (1983) describe tamoxifen as a cell cycle phase specific growth inhibitory agent, which blocks cells in the GO/Gl phase of the cell cycle, and Osborne et al. (1983) suggest that tamoxifen inhibits cell proliferation by invoking a transition delay or block in the early-to-mid-G1 phase of the cell cycle. By the BUdR-mithramycin method applied in this study it is possible to identify the cells which do not participate in cell cycle events. We find that tamoxifen treatment reduces the growth fraction considerably and both cells with a G1 amount of DNA and cells with a G2 amount of DNA are growth arrested. The BUdR-mithramycin technique does not allow a determination of cells arrested in the S phase. This is the first study to demonstrate that both cells with a G1 amount of DNA and a G2 amount of DNA are growth arrested after tamoxifen treatment. By conventional flow cytometry an accumulation of cells in one compartment may indicate a single block in the cell cycle. However, identification of more than one block in the cell cycle is more difficult, since an accumulation in one compartment may be hidden by a decreased entry of cells into the compartment due to a block in another compartment. The BUdR-mithramycin technique is therefore superior to conventional flow cytometry because both non cycling cells with a G1 amount of DNA and a G2 amount of DNA can be identified.
If the MCF-7 model is representative of human breast cancer, the results of these experiments may give valuable information to clinicians for the treatment of this disease. Tamoxifen inhibits growth by reducing the growth fraction and non cycling cells may survive in the tumour for a rather long period of time before they die, indicating the need for long term treatment with tamoxifen. The finding of tamoxifen resistant cells suggests that combined endocrine and cytotoxic treatment may give better overall survival than tamoxifen alone. Knowledge about the effect of tamoxifen on cell cycle kinetic parameters may be useful for the choice and scheduling of combined treatment regimes. 
